Abstract
Extensive studies carried out over the past decade have abundantly confirmed the supposition that human cancer cells, both in vitro and in vivo, have an enormous capacity to develop variant phenotypes which display altered degrees of drug sensitivity. (Goldie and Coldman 1984; Von Hoff 1985). Evidence is accumulating that many of the mechanisms of specific drug resistance that have been identified in experimental systems are also likely to occur in clinical situations (Fojo et al. 1987).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G, Valagussa P (1985) Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 3: 259–275
Bonadonna G, Valagussa P (1987) Current status of adjuvant chemotherapy for breast cancer. Semin Oncol 14: 8–22
Bruce WR, Meeker BE, Veleriote FA (1966) Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37: 233–242
Buzdar A, Smith T, Blumenschein G et al. (1981) Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) for stage II or stage III breast cancer: five year results, In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune and Stratton Orlando, Florida pp 419–426
Coldman AJ, Goldie JH (1983) A model for the resistance of tumour cells to cancer chemotherapeutic agents. Mathematical Biosciences 65: 291–307
Coldman AJ, Goldie JH (1987) Modelling resistance to cancer chemotherapeutic agents. In: Thompson JR, Brown BW (eds) Cancer modelling. Marcel Dekker, New York, pp 315–364
De Vita VT Jr, Hubbard SM, Longo DL (1987) The chemotherapy of lymphomas: looking back, moving forward. Cancer Res 47: 5810–5824
Fisher B, Bauer M, Wickerham DL et al. (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52: 1551–1557
Fojo A, Cornwell M, Cardarelli C et al. (1987) Molecular biology of drug resistance. Breast Cancer Res Treat 9: 5–16
Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733
Goldie JH, Coldman AJ: (1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44: 3643–3653
Hill BT (1982) Biochemical and cell kinetic aspects of drug resistance. In Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol 1. CRC, Boca Raton, Florida, pp 21–54
Hryniuk WM, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281–1288
Hryniuk WM, Figueredo A, Goodyear M (1987) Applications of dose intensity to problem in chemotherapy of breast and colorectal cancer. Semin Oncol 14 [Suppl 4]: 3–11
Jones SE, Moon TE, Bonadonna G et al. (1987) Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history database. Am J Clin Oncol 10: 387–395
Klimo P, Connors JM (1985) MACOP-B for treatment of advanced diffuse large cell lymphoma. Annals Intern Med 102: 596–602
McGuire WL (1987) Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 10: 5–9
Murray N (1987) The importance of dose intensity in lung cancer chemotherapy. Semin Oncol 14 [Suppl 4]: 20–28
Petrelli N, Herrera L, Rustum Y et al. (1987) A prospective randomized Trial of 5-FU versus 5-FU and high dose leucovorin versus 5-FU and metotrexate in previously untreated patients with advanced cerebral carcinoma. J Clin Oncol 5: 1559–1565
Skipper HE (1980) Some thoughts regarding a recent publication by Goldie and Coldman entitled “A mathematic model for relating the drug sensitivity of tumours to their spontaneous mutation rate.” Booklet 9, Southern Research Institute, Birmingham, Alabama
Skipper HE (1987) Comparison of the response of MAM 16/C tumours in mice and breast cancer in women to the same three-drug combination (CAF) Using the same dose intensity units and the same normalization standards, Booklet 14, Southern Research Institute, Birmingham, Alabama
Von Hoff DD (1985) Implications of tumour cell heterogeneity for in vitro drug sensitivity testing. Semin Oncol 12: 327–331.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Goldie, J.H. (1989). New Information on Drug Resistance: Implications for the Adjuvant Treatment of Breast Cancer. In: Senn, HJ., Goldhirsch, A., Gelber, R.D., Osterwalder, B. (eds) Adjuvant Therapy of Primary Breast Cancer. Recent Results in Cancer Research, vol 115. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83337-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-83337-3_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-83339-7
Online ISBN: 978-3-642-83337-3
eBook Packages: Springer Book Archive